drugset / Trial / NCT05126901

Evaluate the Safety and Efficacy of Ferric Maltol Oral Suspension vs. Ferrous Sulfate Oral Liquid in Children and Adolescents Aged 2 to 17 Years With Iron-deficiency Anaemia, With a Single Arm Study in Infants Aged 1 Month to Less Than 2 Years

NCT05126901

Phase 3 Completed 65 enrolled Shield Therapeutics
RandomizedParallel-groupOpen-labelTreatment

Summary

The objective of the study is to compare the safety and gastrointestinal tolerability of ferric maltol oral suspension and ferrous sulfate oral liquid in children and adolescents aged 2 years to 17 years, and assess the safety and tolerability of ferric maltol oral suspension in children 1 month to less than 2 years, in the treatment of iron deficiency anaemia during the 12 weeks treatment period.

Timeline

Start
2021-11-03
Primary completion
2024-06-09
Completion
2024-06-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Ferric maltol Small molecule 0.1 unknown Oral
Subject Ferric maltol Small molecule 2.5 ml Oral
Subject Ferric maltol Small molecule 5 ml Oral
Comparator Ferrous Sulfate Diagnostic / imaging agent 6 mg/kg Oral